Sita Andarini

Dr. Sita Andarini

Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of Indonesia
+1
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2007 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JZJamal Zaini
Jamal Zaini
SASita Andarini
Sita Andarini
MTMinoru Tahara
Minoru Tahara
YSYasuo Saijo
Yasuo Saijo
NINaoto Ishii
Naoto Ishii
TKToshiaki Kikuchi
Toshiaki Kikuchi
The exceptional immunostimulatory capacity of DCs makes them potential targets for investigation of cancer immunotherapeutics. We show here in mice that TNF-α–stimulated DC maturation was accompanied by increased expression of OX40 ligand (OX40L), the lack of which resulted in an inability of mature DCs to generate cellular antitumor immunity. Furthermore, intratumoral administration of DCs modified to express OX40L suppressed tumor growth through the generation of tumor-specific cytolytic T cell responses, which were mediated by CD4+ T cells and NKT cells. In the tumors treated with OX40L-expressing DCs, the NKT cell population significantly increased and exhibited a substantial level of IFN-γ production essential for antitumor immunity. Additional studies evaluating NKT cell activation status, in terms of IFN-γ production and CD69 expression, indicated that NKT cell activation by DCs presenting α-galactosylceramide in the context of CD1d was potentiated by OX40 expression on NKT cells. These results show a critical role for OX40L on DCs, via binding to OX40 on NKT cells and CD4+ T cells, in the induction of antitumor immunity in tumor-bearing mice.

22 April 2005 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
HXHong Xin
Hong Xin
TKToshiaki Kikuchi
Toshiaki Kikuchi
SASita Andarini
Sita Andarini
SOShinya Ohkouchi
Shinya Ohkouchi
TSTakuji Suzuki
Takuji Suzuki
YSYasuo Saijo
Yasuo Saijo
The CX3C chemokine fractalkine (CX3CL1) exists as both a membrane‐bound form promoting firm cell‐cell adhesion and a soluble form chemoattracting leukocytes expressing its receptor CX3CR1. When adenoviral vector expressing mouse fractalkine (AdFKN) was transduced to the tumor cells, fractalkine was expressed as both membrane‐bound form on the tumor cells and soluble form in the supernatant in vitro. Intratumoral injection of AdFKN (1×109PFU/tumor) into C26 and B16F10 tumors resulted in marked reduction of tumor growth compared to control (C26: 86.5%, p<0.001; B16F10: 85.5%, p<0.001). Histological examination of tumor tissues revealed abundant infiltration of NK cells, dendritic cells, and CD8+ T lymphocytes 3 and/or 6 days after treatment with AdFKN. Splenocytes from mice treated by AdFKN developed tumor‐specific cytotoxic T cells, and thereby protected from rechallenging with parental tumor cells. Antitumor effects by AdFKN were completely abrogated in both NK cell‐depleted mice and CD8–/– mice, and partially blocked in CD4–/– mice. These data indicated that fractalkine mediates antitumor effects by both NK cell‐dependent and T cell‐dependent mechanisms. This study suggests that fractalkine can be a suitable candidate for immunogene therapy of cancer because fractalkine induces both innate and adaptive immunity.

1 May 2004 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SASita Andarini
Sita Andarini
TKToshiaki Kikuchi
Toshiaki Kikuchi
MNMio Nukiwa
Mio Nukiwa
PPPrasenohadi Pradono
Prasenohadi Pradono
TSTakuji Suzuki
Takuji Suzuki
TNToshihiro Nukiwa
Toshihiro Nukiwa
OX40 ligand (OX40L), the ligand for OX40 on activated CD4+ T cells, has adjuvant properties for establishing effective T-cell immunity, a potent effector arm of the immune system against cancer. The hypothesis of this study is that in vivo genetic engineering of tumor cells to express OX40L will stimulate tumor-specific T cells by the OX40L-OX40 engagement, leading to an induction of systemic antitumor immunity. To investigate this hypothesis, s.c. established tumors of three different mouse cancer cells (B16 melanoma, H-2b; Lewis lung carcinoma, H-2b; and Colon-26 colon adenocarcinoma, H-2d) were treated with intratumoral injection of a recombinant adenovirus vector expressing mouse OX40L (AdOX40L). In all tumor models tested, treatment of tumor-bearing mice with AdOX40L induced a significant suppression of tumor growth along with survival advantages in the treated mice. The in vivo AdOX40L modification of tumors evoked tumor-specific cytotoxic T lymphocytes in the treated host correlated with in vivo priming of T helper 1 immune responses in a tumor-specific manner. Consistent with the finding, the antitumor effect provided by intratumoral injection of AdOX40L was completely abrogated in a CD4+ T cell-deficient or CD8+ T cell-deficient condition. In addition, ex vivo AdOX40L-transduced B16 cells also elicited B16-specific cytotoxic T lymphocyte responses, and significantly suppressed the B16 tumor growth in the immunization-challenge experiment. All of these results support the concept that genetic modification of tumor cells with a recombinant OX40L adenovirus vector may be of benefit in cancer immunotherapy protocols.

29 March 2006 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
MNMio Nukiwa
Mio Nukiwa
SASita Andarini
Sita Andarini
JZJamal Zaini
Jamal Zaini
HXHong Xin
Hong Xin
MKMasahiko Kanehira
Masahiko Kanehira
TKToshiaki Kikuchi
Toshiaki Kikuchi
Fractalkine (CX3CL1) is a unique membrane‐bound CX3C chemokine that serves as a potent chemoattractant for lymphocytes. The hypothesis of this study is that dendritic cells (DC) genetically modifiedex vivoto overexpress fractalkine would enhance the T cell‐mediated cellular immune response with a consequent induction of anti‐tumor immunity to suppress tumor growth. To prove this hypothesis, established tumors of different mouse cancer cells (B16‐F10 melanoma, H‐2b, and Colon‐26 colon adenocarcinoma, H‐2d) were treated with intratumoral injection of bone marrow‐derived DC that had been modifiedin vitrowith an RGD fiber‐mutant adenovirus vector expressing mouse fractalkine (Ad‐FKN). In both tumor models tested, treatment of tumor‐bearing mice with Ad‐FKN‐transduced DC gave rise to a significant suppression of tumor growth along with survival advantages in the treated mice. Immunohistochemical analysis of tumors treated with direct injection of Ad‐FKN‐transduced DC demonstrated that the treatment prompted CD8+T cells and CD4+T cells to accumulate in the tumor milieu, leading to activation of immune‐relevant processes. Consistent with the finding, the intratumoral administration of Ad‐FKN‐transduced DC evoked tumor‐specific cytotoxic T lymphocytes, which ensued fromin vivopriming of Th1 immune responses in the treated host. In addition, the anti‐tumor effect provided by intratumoral injection of Ad‐FKN‐transduced DC was completely abrogated in CD4+T cell‐deficient mice as well as in CD8+T cell‐deficient mice. These results support the concept that genetic modification of DC with a recombinant fractalkine adenovirus vector may be a useful strategy for cancer immunotherapy protocols.

14 February 2015 in Respirology
Verified
Journal Article
Closed access
PDF file
CLChong‐Kin Liam
Chong‐Kin Liam
SASita Andarini
Sita Andarini
PLPyng Lee
Pyng Lee
JHJames Chung-man Ho
James Chung-man Ho
NCNgo Quy Chau
Ngo Quy Chau
JTJamsak Tscheikuna
Jamsak Tscheikuna

9 December 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
MGMarsia Gustiananda
Marsia Gustiananda
BSBobby Prabowo Sulistyo
Bobby Prabowo Sulistyo
david agustriawandavid agustriawan
david agustriawan
SASita Andarini
Sita Andarini
SARS-CoV-2 and its variants caused the COVID-19 pandemic. Vaccines that target conserved regions of SARS-CoV-2 and stimulate protective T-cell responses are important for reducing symptoms and limiting the infection. Seven cytotoxic (CTL) and five helper T-cells (HTL) epitopes from ORF1ab were identified using NetCTLpan and NetMHCIIpan algorithms, respectively. These epitopes were generated from ORF1ab regions that are evolutionary stable as reflected by zero Shannon’s entropy and are presented by 56 human leukocyte antigen (HLA) Class I and 22 HLA Class II, ensuring good coverage for the Indonesian and world population. Having fulfilled other criteria such as immunogenicity, IFNγ inducing ability, and non-homology to human and microbiome peptides, the epitopes were assembled into a vaccine construct (VC) together with β-defensin as adjuvant and appropriate linkers. The VC was shown to have good physicochemical characteristics and capability of inducing CTL as well as HTL responses, which stem from the engagement of the vaccine with toll-like receptor 4 (TLR4) as revealed by docking simulations. The most promiscuous peptide 899WSMATYYLF907 was shown via docking simulation to interact well with HLA-A*24:07, the most predominant allele in Indonesia. The data presented here will contribute to the in vitro study of T-cell epitope mapping and vaccine design in Indonesia.